Feasibility of a Decentralized Double-Blind Randomized Controlled Trial of Zinc and Nicotinamide Riboside for the Treatment of Idiopathic Pulmonary Fibrosis

The goal of this clinical trial is to learn if a clinical trial for idiopathic pulmonary fibrosis (IPF) can recruit and retain participants from their home to study whether a combination of zinc and nicotinamide riboside can treat iIPF. The main questions are:
Can the investigators recruit participants, and can participants complete study procedures without physically coming into specific clinical trial sites? Can people with IPF experience improvement in symptoms, quality of life, or functioning if they are take these supplements? The investigators will compare zinc and nicotinamide riboside to matched placebos (look-alike substances that contain no drug) to see if these supplements treat symptoms or lung function in people with IPF.
Participants will:
Take drug these supplements twice a day for 24 weeks. Complete pulmonary function testing and six minute walk tests with their own pulmonologists every 12 weeks. Complete a high resolution CT scan at the start and end of the study. Complete video study visits with the research team every 4 weeks. Complete surveys about their symptoms and the number of times they take the medication.

Start Date01 Jan 2025

Sponsor / Collaborator

Cedars-Sinai Health System

NCT04614714

/ Not yet recruitingPhase 2/3IIT

Nicotinamide Riboside and Milk Production in the NICU

Breastfeeding has well-established immunity and developmental benefits for newborns, yet mothers of preterm infants often struggle to provide sufficient breast milk. The investigators hypothesize that supplementing mothers of preterm infants with nicotinamide riboside (NR) during early postpartum will result in increased milk production. NR is a unique precursor to NAD+, which functions in whole-body metabolism, including that which supports the elevated energy demands of lactation. In lactating rats, NR supplementation improved milk quantity and quality, with metabolic benefits for the mother and lasting protective advantages for the offspring. No studies have been conducted to date that explore the short- or long-term use of NR for increasing milk supply in lactating women. This study will follow a small cohort of women and very preterm infants in the NICU throughout two intervention phases-- one in which each mother will randomly receive either NR or a placebo, then the opposite treatment-- to determine the effect of maternal NR supplementation on expressed milk volume and other markers of metabolism.

Start Date01 Dec 2024

Sponsor / Collaborator

University of California, Davis

NCT06324877

/ Not yet recruitingNot ApplicableIIT

Single Arm Open-label Clinical Trial in Ataxia-telangiectasia to Test the Effects of Nicotinamide Riboside on Ataxia Scales, Immune Function, and Neurofilament Light Chain.

Study design: Single arm open-label clinical trial in ataxia-telangiectasia to test the effects of nicotinamide riboside on ataxia scales, immune function, and neurofilament light chain. Study population: 6-10 patients with Ataxia-Telangiectasia. Dose: Nicotinamide riboside 25 mg/kg/day in 3 equal divided doses.
Primary endpoint: Scales for assessment and rating of ataxia (SARA), and International Cooperative Ataxia Rating Scale (ICARS). Improvement of at least ½ standard deviation in key clinical scales which includes either; a) significant improvement in total combined scores from the SARA and ICARS scales, and /or b) significant improvements any aspects of the SARA and ICARS scales individually, especially pertaining to; Postural and gait improvements, Improved syllable speed and articulation, Improved fine motor skills.
Secondary endpoints: Serum analysis of neurofilament light chain (Nfl), Type 1 Interferon (INFs) epigenetic signature

Start Date01 May 2024

Sponsor / Collaborator

The University of Queensland

100 Clinical Results associated with Nicotinamide riboside

100 Translational Medicine associated with Nicotinamide riboside

100 Patents (Medical) associated with Nicotinamide riboside

1,308

Literatures (Medical) associated with Nicotinamide riboside

01 Apr 2025·BONE

The protection of nicotinamide riboside against diabetes mellitus-induced bone loss via OXPHOS

Article

Author: Dai, Shiyou ; Meng, Xiangyuan ; Yang, Xingxiang ; Gao, Tianlin ; Gong, Jianbao ; Zhang, Junwei ; Tian, Chunyan ; Xie, Chenqi ; Gao, Jie

Diabetes mellitus is a global disease that results in various complications, including diabetic osteoporosis. Prior studies have indicated a correlation between low levels of nicotinamide adenine dinucleotide (NAD⁺) and diabetes-related complications. Nicotinamide riboside (NR), a widely utilized precursor vitamin of NAD⁺, has been demonstrated to enhance age-related osteoporosis through the Sirt1/FOXO/β-catenin pathway in osteoblast progenitors. However, the impact of NR on bone health in diabetes mellitus remains unclear. In this study, we assessed the potential effects of NR on bone in diabetic mice. NR was administered to high-fat diet (HFD)/streptozotocin (STZ)-induced type 2 diabetic mice (T2DM), and various parameters, including metabolic indicators, bone quality, bone metabolic markers, and RNA sequences, were measured. Our findings confirmed that HFD/STZ-induced T2DM impaired bone microstructures, resulting in bone loss. NR effectively ameliorated insulin resistance, improved bone microarchitecture, and bone quality, reduced bone resorption, enhanced the Forkhead box O (FOXO) signaling pathway, mitigated the nuclear factor kappa B (NF-kB) signaling pathway, and ameliorated the disorder of the oxidative phosphorylation process (OXPHOS) in diabetic mice. In conclusion, NR demonstrated the capacity to alleviate T2DM-induced bone loss through the modulation of OXPHOS in type 2 diabetic mice. Our results underscore the potential of NR as a therapeutic target for addressing T2DM-related bone metabolism and associated diseases. Further cell-based studies under diabetic conditions, such as in vitro cultures of key cell types (e.g., osteoblasts and osteoclasts), are necessary to validate these findings.

01 Mar 2025·JOURNAL OF NUTRITIONAL BIOCHEMISTRY

Enhancing wound healing via modulation of autophagy-induced apoptosis: the role of nicotinamide riboside and resveratrol in streptozotocin-treated diabetic rat

Article

Author: Maleki, Mohammad Hasan ; Esmaeili, Nafiseh ; Meybodi, Seyed Mohammadmahdi ; Dastghaib, Sanaz ; Mazhari, Seyed Amirhossein ; Siri, Morvarid ; Dehghanian, Amirreza ; Aryanian, Zeinab ; Naseh, Maryam ; Saviri, Fatemeh Ghaderi

Impaired wound healing from diabetes mellitus (DM) causes lower limb amputations, posing clinical, social, and economic issues. Hypoxia and advanced glycation end products cause autophagy and apoptosis dysregulation, which delays wound healing. The study will test systemic and topical Nicotinamide Riboside (NR) and Resveratrol (RSV) for the capacity to modulate autophagy and apoptosis via the SIRT-1-FOXO1 pathway and improve diabetic wound healing. About 54 male Sprague-Dawley rats were separated into control, diabetic (T1D), T1D-Gel-Base, T1D-NR, T1D-RSV, and T1D-NR+RSV groups. Rats were gavaged with 50 mg/kg/day RSV and 300 mg/kg/day NR for 5 weeks before having their wounds topically treated with 5% NR and RSV gel for 15 days after diabetes induction. Biochemical, histomorphometric, and stereological assays were conducted. The mRNA expressions of SIRT-1, FOXO1, VEGF, BAX, Cas3, Bcl-2, Beclin1, LC3IIβ, P62, and ATG5 were examined by qRT-PCR. NR and RSV improved diabetic rat wound closure. Diabetic rats treated with NR and RSV had significantly higher LC3IIβ, VEGEF, Bcl-2, and SIRT-1 mRNA levels. Bcl-2, p62, and ATG5 were regulated whereas BAX and Cas 3 were reduced. Stereological investigations showed epidermal, dermal, collagen bundle, vascular, and fibroblast density enhancements. This study highlights the potential of NR and RSV, acting as SIRT-1 activators, in improving diabetic wound healing by regulating SIRT-1-FOXO1-mediated autophagy and apoptosis. These findings offer valuable insights for developing targeted strategies to enhance diabetic wound healing. The combination of NR and RSV showed promising effects, suggesting a potential therapeutic approach for improving diabetic wound healing.

01 Jan 2025·JOURNAL OF PATHOLOGY

Nicotinamide riboside targets mitochondrial unfolded protein response to reduce alcohol‐induced damage in Kupffer cells

Article

Author: Kang, Hyunju ; Lee, Ji‐Young ; Park, Young‐Ki ; Lee, Jaeeun ; Woo, Hayoung

Abstract:

The pathogenesis of alcohol‐related liver disease (ALD) is closely linked to mitochondrial dysfunction and impaired cellular energy metabolism. In this study, we explored how ethanol triggers inflammation, oxidative stress, and mitochondrial dysfunction in Kupffer cells, i.e.hepatic resident macrophages, primarily focusing on the mitochondrial unfolded protein response (UPRmt) using immortalized mouse Kupffer cells (ImKCs) and mouse primary KCs. The UPRmt is a cellular defense mechanism activated in response to the perturbation of mitochondrial proteostasis to maintain mitochondrial integrity and function by upregulating the expression of mitochondrial chaperones and proteases. We also determined whether nicotinamide riboside (NR), a NAD+ precursor, could mitigate ethanol‐triggered cellular damage. When ImKCs were exposed to 80 mm ethanol for 72 h, they displayed inflammation, oxidative stress, and impaired mitochondrial function with decreased mitochondrial content and deformed mitochondrial crista structure. NR, however, counteracted the effects of ethanol. Furthermore, ethanol increased mRNA and protein levels of UPRmt genes, such as mitochondrial chaperones and proteases, which were attenuated by NR. Notably, the ethanol‐induced shift in the entry of activating transcription factor 5 (ATF5), a putative transcriptional regulator of UPRmt, to the nucleus from the mitochondria was abolished by NR. The induction of UPRmt genes by ethanol was significantly repressed when Atf5 was knocked down, indicating the role of ATF5 in the induction of UPRmt genes in ImKCs exposed to ethanol. We also confirmed the induction of UPRmt gene expression in mouse and human livers exposed to alcohol. Our findings demonstrate the ability of NR to alleviate ethanol‐induced oxidative stress, inflammation, and mitochondrial dysfunction, partly by modulating the ATF5‐dependent UPRmt pathway in ImKCs, suggesting its potential for ALD therapy. © 2024 The Pathological Society of Great Britain and Ireland.

News (Medical) associated with Nicotinamide riboside

04 Feb 2025

·www.prnewswire.com

NexGen Health Introduces Niagen Plus IV Therapy: Revolutionizing Cellular Health and Anti-Aging in Silicon Valley

NexGen Health in San Jose introduces Niagen Plus IV Therapy, an advanced treatment that boosts cellular health, enhances energy, and combats aging by replenishing NAD+ levels using nicotinamide riboside (NR). This innovative therapy complements NexGen Health's regenerative medicine offerings, setting a new standard for wellness in Silicon Valley. SAN JOSE, Calif., Feb. 4, 2025 /PRNewswire/ -- NexGen Health, Silicon Valley's premier destination for cutting-edge regenerative wellness, is proud to announce the launch of Niagen Plus IV Therapy, an innovative treatment designed to enhance cellular health, boost energy, and combat the effects of aging. This groundbreaking therapy harnesses the power of nicotinamide riboside (NR), a key precursor to NAD+ (Nicotinamide Adenine Dinucleotide), combined with IV delivery for optimal absorption and faster results. The Science Behind Niagen Plus IV Therapy Continue Reading NexGen Health NAD+ is a vital coenzyme found in all living cells, responsible for energy production, DNA repair, and cellular regeneration. As people age, NAD+ levels naturally decline, leading to fatigue, cognitive decline, and other age-related conditions. Niagen Plus IV Therapy replenishes NAD+ levels by delivering nicotinamide riboside (NR) directly into the bloodstream, bypassing the digestive system to ensure maximum efficacy and rapid cellular uptake. "Our Niagen Plus IV Therapy is a game-changer for patients seeking to improve energy levels, optimize cognitive function, and support overall longevity," said Ilbra Petros, Director of NexGen Health." This treatment is perfect for anyone looking to combat the cellular effects of aging and enhance their vitality." Key Benefits of Niagen Plus IV Therapy Cellular Regeneration: Restores NAD+ levels to support healthier, more resilient cells. Enhanced Energy: Improves mitochondrial function to combat fatigue and sustain energy throughout the day. Cognitive Performance: Boosts brain health, improving focus, memory, and overall mental clarity. Anti-Aging Effects: Supports DNA repair, reduces oxidative stress, and promotes healthy aging. Synergistic Wellness: Complements other treatments offered at NexGen Health, such as NAD therapy, peptides, and IV nutrient infusions. A New Standard of Care in Silicon Valley Located in the heart of San Jose, NexGen Health is renowned for its personalized, concierge-level wellness services. With the addition of Niagen Plus IV Therapy, NexGen Health continues to lead the way in advanced regenerative medicine, offering residents of Silicon Valley and beyond an opportunity to optimize their health at the cellular level. "Niagen Plus IV Therapy represents the future of anti-aging and wellness," added Ilbra. "We are thrilled to bring this innovative treatment to the Bay Area, providing our patients with a scientifically-backed solution to improve their quality of life and unlock their full potential." About NexGen Health NexGen Health is a state-of-the-art wellness center located in San Jose, CA, specializing in advanced regenerative medicine and innovative health solutions. From NAD therapy and peptide treatments to IV nutrient infusions and comprehensive wellness consultations, NexGen Health offers cutting-edge services tailored to individual patient needs. As a leader in cellular health and anti-aging therapies, NexGen Health combines the latest advancements in medical science with concierge-level care to deliver exceptional results. Schedule Your Niagen Plus IV Therapy Consultation Today To learn more about Niagen Plus IV Therapy or schedule a consultation, visit NexGen Health online at or call (408) 400-2967. Media Contact: Ilbra Petros NexGen Health 408-400-2967 [email protected] SOURCE NexGen Health WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

22 Nov 2024

·www.drugs.com

Could a Vitamin Be Effective Treatment for COPD?

FRIDAY, Nov. 22, 2024 -- A daily dose of vitamin B3 reduced inflammation in the lungs of patients with COPD , Danish researchers report. "This is significant, because inflammation can lead to reduced lung function in these patients," said researcher Morten Scheibye-Knudsen , of the University of Copenhagen. Patients with COPD -- the full name of which is chronic obstructive pulmonary disease -- are more likely to get pneumonia, influenza and other serious respiratory infections, which can be fatal. The new study included 40 participants with COPD and a control group of 20 healthy volunteers. They received either 2 grams a day of nicotinamide riboside -- a member of the vitamin B3 family -- or a placebo. After six weeks, researchers saw a 53% drop in a marker of inflammation known as interleukin 8, or IL 8. After 12 more weeks of vitamin therapy, the effect increased by 63%. "In other words," the researchers said in a university news release, "The group treated with vitamin B3 experienced reduced lung inflammation during the study." More study will be needed to confirm the findings and determine the long-term effect of nicotinamid riboside in treating COPD, Scheibye-Knudsen said. During the study, the team also observed that COPD patients have lower blood levels of a chemical called NAD, which appears to play a role in the aging process. NAD levels rose with vitamin B3 treatment and signs of cellular aging slowed, researchers reported Nov. 15 in the journal Nature Aging . "As we age, we seem to metabolize a molecule known as NAD," Scheibye-Knudsen said. "The loss of this molecule is also seen after DNA damage, for instance the type of damage associated with smoking." As such, he said NAD may be a target for future research and treatment. Meanwhile, his team plans a larger study to confirm the initial findings. "We hope this research will pave the way for new treatment options for COPD patients," Scheibye-Knudsen said. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical Result

26 Sep 2024

·www.businesswire.com

ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference

LOS ANGELES--( BUSINESS WIRE )--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on healthy-aging research, today announced that Rob Fried, CEO of ChromaDex and Founder of Tru Niagen, will participate in a fireside chat moderated by Sean McGowan, Senior Analyst at Roth Capital Partners, at the Lytham Partners Fall 2024 Investor Conference. Wesley Yu, Vice President of Finance at ChromaDex, and Mr. Fried will also host virtual one-on-one meetings with investors. Company Webcast The webcasted fireside chat will take place at 1:15 PM ET on Tuesday, October 1, 2024. The webcast can be accessed at https://app.webinar.net/7yrd0odReoK or on the Company's website at chromadex.com. The webcast will also be available for replay following the event. 1x1 Meetings Mr. Fried and Mr. Yu will participate in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register for the event at https://lythampartners.com/fall2024invreg . Further information on the conference is available at https://lythampartners.com/fall2024 . For additional information on ChromaDex, visit www.chromadex.com . About ChromaDex: ChromaDex Corp. (NASDAQ:CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, comprised of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality. Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship ingredient, Niagen (patented nicotinamide riboside, or NR), the most efficient and superior-quality NAD+ booster available. Niagen is the active ingredient in ChromaDex’s consumer products, sold as the brand Tru Niagen ® , the number one healthy-aging NAD+ supplement in the United States † . Clinically proven to increase NAD+ levels, Tru Niagen is helping people around the world transform the way they age (available at www.truniagen.com ). ChromaDex’s robust patent portfolio protects NR and other NAD+ precursors. ChromaDex maintains a website at www.chromadex.com , to which ChromaDex regularly publishes copies of its press releases, news, and financial information. † Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 3/1/2023-2/29/2024).

Oligonucleotide

100 Deals associated with Nicotinamide riboside

External Link

KEGG	Wiki	ATC	Drug Bank
-	Nicotinamide riboside	A11HA01	DB14933

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cardiotoxicity	Phase 2	NO	ChromaDex, Inc.	16 Mar 2023
Heart Failure	Phase 2	NO	ChromaDex, Inc.	16 Mar 2023
Myocardial injury	Phase 2	NO	ChromaDex, Inc.	16 Mar 2023
Head and Neck Neoplasms	Phase 2	US	ChromaDex, Inc.	08 Nov 2019
Metastatic breast cancer	Phase 2	US	ChromaDex, Inc.	08 Nov 2019
Metastatic endometrial cancer	Phase 2	US	ChromaDex, Inc.	08 Nov 2019
Peripheral Nervous System Diseases	Phase 2	US	ChromaDex, Inc.	08 Nov 2019
Platinum-Resistant Ovarian Carcinoma	Phase 2	US	ChromaDex, Inc.	08 Nov 2019
Acute febrile illness	Phase 2	NO	ChromaDex, Inc.	01 Oct 2019
Critical Illness	Phase 2	NO	ChromaDex, Inc.	01 Oct 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03743636 (NICE, CTgov)	Phase 3	Peripheral Arterial Disease	90	Nicotinamide riboside+Resveratrol (Nicotinamide Riboside + Resveratrol)	arhcxtxmic(omwegnofgn) = wdygqdpnad rjtscgcvjr (aifetvqwcx, epymuihtwb - erajbypzyp) View more	-	14 Jan 2025
				Placebo+Nicotinamide riboside (Nicotinamide Riboside + Placebo)	arhcxtxmic(omwegnofgn) = jvunvrjjdz rjtscgcvjr (aifetvqwcx, waxfdxykvw - jtcbgocsef) View more
Biospace Manual	Phase 2	Peripheral Arterial Disease	90	Nicotinamide Riboside	krckpjfjda(bsqnuhfjcd) = qxjcuqxibi adkyddalvo (xauvmhxtry )	Positive	24 Jun 2024
				Nicotinamide Riboside combination with resveratrol	-
NCT03912220 (CTgov)	Phase 2	Small Fiber Neuropathy	45	Nicotinamide riboside (Nicotinamide Riboside)	skktvyxpjk(swcbknbedn) = qziknnmuhm ndrrddvzkk (ozxgtvtcan, hojqyqpccv - mqszpbvnus) View more	-	06 Jun 2024
				Placebo Oral Tablet (Placebo)	skktvyxpjk(swcbknbedn) = xzcedabyqr ndrrddvzkk (ozxgtvtcan, diqapzyhjb - idzpatidbe) View more
NCT04112043 (CTgov)	Phase 1	Hypertension	147	Walking Exercise+Nicotinamide Riboside (NR) (NR Plus Walking Exercise)	lxhgzcpizb(mxjkrrechw) = mgrhgnspru ptndhwlkzr (oscodilbkz, vbgzlesalb - hlcrdpajpj) View more	-	06 Jun 2024
				Walking Exercise (Walking Exercise Plus Placebo)	lxhgzcpizb(mxjkrrechw) = vcpbsilrdm ptndhwlkzr (oscodilbkz, ywdwnsgswg - rktrlmpvyq) View more
ATS2024	Not Applicable	Sepsis	-	Nicotinamide Riboside (NR) 30 mg/kg	igkpjkvfae(fcywakffxr) = pqgkgwzfwi mrwpiacmuh (kfxxpvdjxy )	-	19 May 2024
				H2O control	igkpjkvfae(fcywakffxr) = hoytymhktw mrwpiacmuh (kfxxpvdjxy )
NCT03151707 (CTgov)	Phase 4	-	11	Nicotinamide Riboside	gwuaxaiexr(qokfkwmmnt) = dbtspoejco npwbzzywaa (ubflqkhboi, agtckyiozr - xznnezjddz) View more	-	05 Mar 2024
NCT04818216 (NIRVANA, CTgov)	Phase 2	COVID-19 \| Acute Kidney Injury	28	Placebo (Placebo Group)	bksjdfomfi(dlthwxloll) = pncxmoyufo ncavtnetjx (hjhrxeyrxx, fmenhvkecy - crpzubniaf) View more	-	26 Dec 2023
				Nicotinamide riboside (Nicotinamide Riboside Group)	bksjdfomfi(dlthwxloll) = urxbygznkc ncavtnetjx (hjhrxeyrxx, qxggpwxgaf - mcywkksxgm) View more
Biospace Manual	Phase 1	Parkinson Disease	20	Niagen 3000 mg	qgccismqss(qasimivrrs) = High-dose NR was safe and well-tolerated with no related adverse events. njmnmoblce (witffvubqq ) View more	Positive	30 Nov 2023
				placebo
ARVO2023	Phase 2	Glaucoma nicotinamide adenine dinucleotide (NAD)	118	Nicotinamide Riboside (NR) 300mg/day	ulsjugsuug(fcitsdujxp) = Two patients, one in each group, developed gastrointestinal upset cnnlzjbnil (mvlaetrsuz )	Positive	01 Jun 2023
NCT03642990 (CTgov)	Phase 2	Metastatic endometrial cancer \| Metastatic breast cancer \| Peripheral Nervous System Diseases ... View more	5	Nicotinamide Riboside	joopdnalrl(bzuxyflenm) = vzitkfwniq idovdmdspk (yclyzckuwu, sxauuyinrp - fvhxvwaprv) View more	-	12 Apr 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis